Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire’s Vyvanse Getting Increased Attention From ADHD Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Attention deficit/hyperactivity disorder drug gained a 2.8 percent share of the market two months after its launch, Shire reports.

You may also be interested in...



FDA Approves Shire’s Once-daily Vyvanse For Adult ADHD

British biopharma had pegged nearly one-third of drug’s sales to off-label adult usage.

FDA Approves Shire’s Once-daily Vyvanse For Adult ADHD

British biopharma had pegged nearly one-third of drug’s sales to off-label adult usage.

Shire Submits Vyvanse sNDA For Adult ADHD

The company plans to announce data from a Phase III trial in adults in the fourth quarter.

Topics

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel